search
Back to results

Ultrafast Ultrasound Imaging Assesment of Carotid Plaque Neovascularization (ULTRA-VASC)

Primary Purpose

Carotid Stenosis, Carotid Artery Diseases, Carotid Atherosclerosis

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
contrast enhanced ultrafast ultrasound imaging
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Carotid Stenosis focused on measuring Carotid Stenosis, Endarterectomy, Carotid, Carotid Arteries, Carotid Artery, Internal, Stroke, Ultrasonography, Ultrasonography, Doppler, diagnostic imaging, Prognosis, Contrast Media

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The patient is over 18
  • The patient is scheduled for carotid endarterectomy within 30 days at most
  • The patient has a social security system

Exclusion Criteria:

  • Non-atheromatous carotid stenosis (radiation)
  • Contraindication of the use of SonoVue ultrasound contrast media. Hypersensitivity to the active ingredient or any of the following excipients: Macrogol 4000; Distearoylphosphatidylcholine; Dipalmitoylphosphatidylglycerol sodium; Palmitic acid.
  • The patient has any of the following conditions: right-left shunt, severe pulmonary hypertension (pulmonary blood pressure > 90 mm Hg), uncontrolled systemic hypertension and respiratory distress syndrome.
  • Lack of social security coverage, patient under justice
  • Allergy to ultrasound gel
  • Pregnancy. (As a precautionary measure, it is best to avoid using SonoVue during pregnancy according to SPC)
  • Patient under guardianship or curatorship or under the protection of justice.
  • Patient unable or unwilling to give written consent

Sites / Locations

  • Hopital europeen Georges-PompidouRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Carotid plaque or stenosis ultrasound enhanced UF assesment

Arm Description

symptomatic or asymptomatic patients with atheromatous carotid stenosis scheduled for carotid endarterectomy

Outcomes

Primary Outcome Measures

Neovascularization of the carotid plaque
Correlation BETWEEN the average signal strength of the carotid plaque analyzed after injection of ultrasound contrast medium by three-dimensional probe with UF-Doppler AND the number of neovessels determined by histological analysis of the carotid plaque (number of neovessels per section) studied.

Secondary Outcome Measures

Plaque stable or unstable
analyzed after injection of ultrasound contrast medium by three-dimensional probe with UF-Doppler AND the plaque stability according to Oxford criteria
Plaque symptomatic or not
Comparison BETWEEN the average signal strength of the carotid plaque analyzed after injection of ultrasound contrast medium by three-dimensional probe with UF-Doppler AND the symptomatic or asymptomatic status for stroke of the patient

Full Information

First Posted
July 9, 2020
Last Updated
November 15, 2021
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
search

1. Study Identification

Unique Protocol Identification Number
NCT04470687
Brief Title
Ultrafast Ultrasound Imaging Assesment of Carotid Plaque Neovascularization
Acronym
ULTRA-VASC
Official Title
Innovative Applications of Ultrafast Ultrasound Imaging in Peripheral Vascular Pathology: Evaluation of Carotid Plaque Vulnerability by Quantification of Neovascularization
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
March 17, 2021 (Actual)
Primary Completion Date
March 17, 2022 (Anticipated)
Study Completion Date
March 17, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Stroke is the second leading cause of death in the Western world and the leading cause of major lifelong disability. About 15% of strokes are secondary to thrombosis or embolization of an unstable atheromatous carotid plaque. In these symptomatic patients, the degree of carotid stenosis is correlated with the risk of early recurrence. Patients with stenosis over 70% are therefore offered an endarterectomy, an operation to remove carotid plaque, to prevent future strokes[1]. In asymptomatic patients, the degree of stenosis is a limited predictor, and better risk stratification is required to assess the degree of plaque vulnerability and stroke risk of the patient. The therapeutic decision towards endarterectomy in addition to drug therapy is debated because of a variable and dependent benefit/risk balance for each patient. A number of imaging parameters have been studied: ulceration, heterogeneity, vascularization of the plaque for example, but their place is not well defined [2]. The usual evaluation of carotid stenosis is by conventional Doppler ultrasound with calculation of the degree of stenosis according to the NASCET criteria. For symptomatic stenoses the intervention is recommended when above 70% and is discussed from 50% to 70% of NASCET stenosis degree. For asymptomatic stenoses, the procedure is discussed when above 60% taking into account the patient's life expectancy, the risk of the surgery and the unstable nature of the plaque [2]. Destabilization of the carotid plaque is partially induced by inflammation associated with neo-vascularization. The detection of these new vessels by conventional contrast ultrasound has already shown a distinction between stable and unstable plaques, by the presence or absence of microbubbles in the plaque. However, this assessment is not very precise and only the most vascularized plaques can be detected. Ultrafast ultrasound Imaging is a new ultrasonic Imaging modality that allows detecting low speed flows, a tiny vascular structure within the vessel wall. RESEARCH HYPOTHESIS Plaques neo-vascularization would be more precisely detected and characterized by ultrafast imaging coupled with microbubble injection than conventional ultrasound imaging. A better assessment of plaque instability could improve the selection of patients for carotid endarterectomy and increase the benefit/risk ratio of this preventive surgery.
Detailed Description
see above

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carotid Stenosis, Carotid Artery Diseases, Carotid Atherosclerosis, Carotid Artery Plaque, Atheroma; Carotid Artery
Keywords
Carotid Stenosis, Endarterectomy, Carotid, Carotid Arteries, Carotid Artery, Internal, Stroke, Ultrasonography, Ultrasonography, Doppler, diagnostic imaging, Prognosis, Contrast Media

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Carotid plaque or stenosis ultrasound enhanced UF assesment
Arm Type
Experimental
Arm Description
symptomatic or asymptomatic patients with atheromatous carotid stenosis scheduled for carotid endarterectomy
Intervention Type
Device
Intervention Name(s)
contrast enhanced ultrafast ultrasound imaging
Intervention Description
Ultrasound contrast medium: SonoVue 8µL/mL (Bracco International BV) Ultrasound scanner: Aixplorer® device marketed by SuperSonic Imagine©, CE Doppler UltraFast™Doppler, contrast ultrasound (CEUS), color Doppler and ultra-sensitive energy Doppler, high-performance directional energy Doppler, Elastography ShearWave™ UF-Doppler (UltraFast-Doppler) and microbubble injection (SonoVue) Apparatus for performing the UF Doppler sequence: Aixplorer, manufacturer : Supersonic Imagine, Aix-en-Provence, France, CE Marking. 3D RCA dedicated vascular probe with dedicated Doppler sequences
Primary Outcome Measure Information:
Title
Neovascularization of the carotid plaque
Description
Correlation BETWEEN the average signal strength of the carotid plaque analyzed after injection of ultrasound contrast medium by three-dimensional probe with UF-Doppler AND the number of neovessels determined by histological analysis of the carotid plaque (number of neovessels per section) studied.
Time Frame
end of inclusions
Secondary Outcome Measure Information:
Title
Plaque stable or unstable
Description
analyzed after injection of ultrasound contrast medium by three-dimensional probe with UF-Doppler AND the plaque stability according to Oxford criteria
Time Frame
end of inclusions
Title
Plaque symptomatic or not
Description
Comparison BETWEEN the average signal strength of the carotid plaque analyzed after injection of ultrasound contrast medium by three-dimensional probe with UF-Doppler AND the symptomatic or asymptomatic status for stroke of the patient
Time Frame
end of inclusions

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient is over 18 The patient is scheduled for carotid endarterectomy within 30 days at most The patient has a social security system Exclusion Criteria: Non-atheromatous carotid stenosis (radiation) Contraindication of the use of SonoVue ultrasound contrast media. Hypersensitivity to the active ingredient or any of the following excipients: Macrogol 4000; Distearoylphosphatidylcholine; Dipalmitoylphosphatidylglycerol sodium; Palmitic acid. The patient has any of the following conditions: right-left shunt, severe pulmonary hypertension (pulmonary blood pressure > 90 mm Hg), uncontrolled systemic hypertension and respiratory distress syndrome. Lack of social security coverage, patient under justice Allergy to ultrasound gel Pregnancy. (As a precautionary measure, it is best to avoid using SonoVue during pregnancy according to SPC) Patient under guardianship or curatorship or under the protection of justice. Patient unable or unwilling to give written consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tristan MIRAULT, MD, PhD
Phone
+33 (0)1.56.09.26.51
Email
tristan.mirault@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Laura LE MAO, MSc
Phone
+33.1.56.09.54.97
Email
laura.le-mao@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tristan MIRAULT, MD, PhD
Organizational Affiliation
Hopital europeen Georges-Pompidou
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hopital europeen Georges-Pompidou
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tristan MIRAULT, MD, PhD
Phone
+33.1.56.09.58.32
Email
tristan.mirault@aphp.fr
First Name & Middle Initial & Last Name & Degree
Helene MORTELETTE, PhD
Phone
+33.1.56.09.38.72
Email
helene.mortelette@aphp.fr
First Name & Middle Initial & Last Name & Degree
Tristan MIRAULT, MD, PhD
First Name & Middle Initial & Last Name & Degree
Lina KHIDER, MD, MSc
First Name & Middle Initial & Last Name & Degree
Guillaume GOUDOT, MD, PhD
First Name & Middle Initial & Last Name & Degree
Emmanuel MESSAS, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data (IPD) that underlie results in publication could be shared
IPD Sharing Time Frame
Data could be available one year after the last publication
IPD Sharing Access Criteria
Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team. Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and potentially commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization.

Learn more about this trial

Ultrafast Ultrasound Imaging Assesment of Carotid Plaque Neovascularization

We'll reach out to this number within 24 hrs